CytomX Therapeutics (CTMX) Receivables (2014 - 2026)

CytomX Therapeutics' Receivables history runs 13 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Receivables rose 9.71% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 9.71% YoY) and the FY2025 annual result came in at $2.5 million, down 19.58% from the prior year.
• Receivables was $2.1 million for Q1 2026 at CytomX Therapeutics, down from $2.5 million in the prior quarter.
• Across five years, Receivables topped out at $35.0 million in Q4 2022 and bottomed at $1.0 million in Q2 2022.
• A 5-year average of $4.6 million and a median of $2.1 million in 2026 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 4330.38% — and 2023, when it tumbled 93.71%.
• CytomX Therapeutics' Receivables stood at $35.0 million in 2022, then tumbled by 93.71% to $2.2 million in 2023, then jumped by 42.05% to $3.1 million in 2024, then retreated by 19.58% to $2.5 million in 2025, then slipped by 14.6% to $2.1 million in 2026.
• Business Quant data shows CTMX's Receivables at $2.1 million in Q1 2026, $2.5 million in Q4 2025, and $1.6 million in Q3 2025.